Highlights
- Public artifacts should be citable and reproducible.
- Commercial artifacts require separate evidence and license terms.
- The boundary protects both open trust and future IP value.
Artifact card
| Track | Open ecosystem / commercial IP |
|---|---|
| Status | Draft |
| Interface/spec | Pending |
| Benchmark schema | Pending |
| Known limitations | Listed in release manifest |
| Version compatibility | Pending |
| External archive | Archive pending |
Abstract
This article separates public research artifacts from commercial IP boundaries for ProCore and ASICKit.
Motivation
This article defines a PCCX research artifact that can be cited, audited, and updated without turning draft evidence into marketing copy.
Evidence snapshot
The article records what is currently known, what remains unresolved, and what artifact must exist before stronger claims are made.
Method outline
The release package should include metadata, source logs, scripts, figures, checksums, citation files, and a plain-English limitation note.
Reproduce this result
- Open the external archive record when published.
- Download the manifest and artifact bundle.
- Run the parser or notebook listed in the manifest.
- Regenerate the figure and compare the checksum.
External archive
| Provider | Zenodo planned |
|---|---|
| Status | Archive pending |
| DOI | Pending |
| Record | Not yet published |
Code availability
Analysis scripts and raw parsers should be released through the project repository or a DOI-backed external archive, then linked here.
Commercial relevance
Clarifies the path from public credibility to Evaluation, NRE, ProCore, and ASICKit licensing.
References
- PCCX Research. Article archive record, version 0.1.0-draft.
- PCCX artifact metadata and citation records.